A randomized, double-blind, double-dummy, safety crossover trial comparing cumulative doses up to 96 μg of formoterol delivered via an HFA-134a-propelled pMDI vs. same cumulative doses of formoterol DPI and placebo in asthmatic patients

Respiration

Volumn 72, Issue SUPPL. 1, 2005, Pages 28-34

  Molimard, M ^a,f   Guenole E ^b   Duvauchelle, T ^c   Vicaut, E ^d   Lefrancois G ^e  

^a BORDEAUX UNIVERSITY HOSPITAL   (France)

^b Therapharm Recherches   (France)

^c Aster Cephac   (France)

^d HÔPITAL LARIBOISIÈRE   (France)

^e Chiesi   (France)

^f HÔPITAL PELLEGRIN   (France)

Author keywords

Cardiac safety; Cumulative doses; Dry powder inhaler; Formoterol; Hydrofluoroalkanes; Pressurized metered dose inhaler; QTc interval

Indexed keywords

FORMOTEROL; NORFLURANE;

ADULT; ARTICLE; CARDIOTOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DELIVERY SYSTEM; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG SAFETY; ELECTROCARDIOGRAPHY MONITORING; FEMALE; HEADACHE; HEART PALPITATION; HEART RATE VARIABILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; MEDICAL EXAMINATION; METERED DOSE INHALER; MODERATE PERSISTENT ASTHMA; MULTICENTER STUDY; PATIENT MONITORING; PHASE 2 CLINICAL TRIAL; POWDER INHALER; PRIORITY JOURNAL; QRS COMPLEX; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL; SEVERE PERSISTENT ASTHMA; TACHYCARDIA; TREMOR;

ADULT; AEROSOL PROPELLANTS; ASTHMA; BLOOD GLUCOSE; BLOOD PRESSURE; BRONCHODILATOR AGENTS; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ELECTROCARDIOGRAPHY; ETHANOLAMINES; FEMALE; HEART RATE; HUMANS; HYDROCARBONS, FLUORINATED; MALE; METERED DOSE INHALERS; MIDDLE AGED; NEBULIZERS AND VAPORIZERS; POTASSIUM; POWDERS;

EID: 20944444731     PISSN: 00257931     EISSN: None     Source Type: Journal    
DOI: 10.1159/000083690     Document Type: Article

References (24)

1. USA National Institute of Health National Heart LaBI: Report No. 95-3659. 1995.
2. Bousquet J: Modulite®: Simplifying the changeover. Respir Med 2002;96:S1-S2.
3. Sichletidis L, Kottakis J, Marcou S, et al: Bronchodilatory responses to formoterol, ipratropium, and their combination in patients with stable COPD. Int J Clin Pract 1999;53:185-188.
4. Ganderton D, Lewis D, Davies R, Meakin B, Brambilla G, Church T: Modulite®: A means of designing the aerosols generated by pressurized metered dose inhalers. Respir Med 2002;96(suppl D):S3-S8.
5. Montreal Protocol [Accessed 2002, Apr 19] on line. Available from: http://www.unep.org/ozone/pdf/Montreal-Protocol2000.pdf.
6. Magnussen H: Budesonide Modulite®: Improving the changeover to CFC-free treatments. Respir Med 2003;97:S1-S3.
7. Woodcock A, Acerbi D, Poli D: Modulite® technology: Pharmacodynamic and pharmacokinetic implications. Respir Med 2002;96(suppl D):S9-S15.
8. Bartow RA, Brogden RN: Formoterol: An update of its pharmacological properties and therapeutic efficacy in the management of asthma. Drugs 1998;55:303-322.
9. Sheffer AL: Global strategy for asthma management and prevention. NHLBI/WHO Workshop report (95-3659). NIH 1995.
10. Burgess C, Ayson M, Rajasingham S, Crane J, Della Cioppa G, Till MD: The extrapulmonary effects of increasing doses of formoterol in patients with asthma. Eur J Clin Pharmacol 1998;54:141-147.
11. Totterman KJ, Huhti L, Sutinen E, Backman R, et al: Tolerability to high doses of formoterol and terbutaline via Turbuhaler™ for 3 days in stable asthmatic patients. Eur Resp J 1998;12:573-579.
12. Bremner P, Woodman K, Burgess C, et al: A comparison of the cardiovascular and metabolic effects of formoterol, salbutamol and fenoterol. Eur Resp J 1993;6:204-210.
13. Lecaillon JB, Kaiser G, Palmisano M, Morgan J, Della Cioppa G: Pharmacokinetics and tolerability of formoterol in healthy volunteers after a single high dose of Foradil® dry powder inhalation via aerolizer™. Eur J Clin Pharmacol 1999;55:131-138.
14. Maesen FPV, Costongs R, Smeets JJ, Brombacher PJ, Zweers PGMA: The effect of maximal doses of formoterol and salbutamol from a metered dose inhaler on pulse rates, ECG and serum potassium concentrations. Chest 1991;99:1367-1373.
15. Grzelewska-Rzymowska I, Malolepszy J, de Molina M, Sladek K, Zarkovic J, Siergiejko Z: Equivalent asthma control and systemic safety of inhaled budesonide delivered via HFA-134a or CFC propellant in a broad range of doses. Respir Med 2003;97(suppl D):S10-S19.
16. Ganderton D, Lewis D, Davies R, Meakin B, Church T: The formulation and evaluation of a CFC-free budesonide pressurised metered dose inhaler. Respir Med 2003;97(suppl D):S4-S9.
17. Vastagh E, Kuna P, Calistru P, Bogdan MA: Efficacy and safety of inhaled budesonide delivered once or twice daily via HFA-134a in mild to moderate persistent asthma in adult patients. Comparision with budesonide CFC. Respir Med 2003;97(suppl D):S20-S28.
18. Ind PW, Villasante C, Shiner RJ, Pietinalho A, Boszormenyl NG, Soliman S, Selroos O: Safety of formoterol by Turbuhaler® as reliever medication compared with terbutaline in moderate asthma. Eur Respir J 2002;20:859-866.
19. Cazzola M, Imperatore F, Salzillo A, Di Perna F, Calderaro F, Imperatore A, Matera MG: Cardiac effects of formoterol and salmeterol in patients suffering from COPD with preexisting cardiac arrhythmias and hypoxemia. Chest 1998;114.
20. Rabe KR: Formoterol in clinical practice - safety issues. Respir Med 2001;95:S21-S25.
21. Sarma JS, Sarma RJ, Bilitch M, Katz D, Song SL: An exponential formula for heart rate dependence of QT interval during exercise and cardiac pacing in humans: Reevaluation of Bazett's formula. Am J Cardiol 1984;54:103-108.
22. Milne JR, Camm AJ, Ward DE, Spurrell RA: Effect of intravenous propranolol on QT interval. A new method of assessment. Br Heart J 1980;43:1-6.
23. Friderici LS: Die Systolendauer im Elektrokardiogramm bei normalen Menschen und bei Herzkranken. Acta Med Scand 1920;53:469-486.
24. Abramson MJ, Walters J, Walters EH: Adverse effects of beta-agonists. Am J Respir Med 2003;2:287-297.